Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection

Jonathan A. Bock, Kimberly J. Fairley, Robert E. Smith, Daniel D. Maeng, James M. Pitcavage, Nicholas A. Inverso, Marc S. Williams

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences